FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367302912> ?p ?o ?g. }

• W4367302912 abstract "<h3>Objective:</h3> Review the University of Kansas Medical Center’s clinical experience using ravulizumab and efgartigimod alpha-fcab for patients with myasthenia gravis. <h3>Background:</h3> Ravulizumab and efgartigmod alpha-fcab are two recently approved medications for the treatment of myasthenia gravis. Though they have been proven to be safe and effective, little has been published since their releases regarding clinicians’ experiences with these medications. <h3>Design/Methods:</h3> After IRB approval was obtained, we performed a retrospective chart review of patients with myasthenia gravis from a single academic center who had received at least one infusion of ravulizumab or efgartigimod alpha-fcab. Demographic, clinical, and therapeutic information was obtained from the charts. Descriptive analysis will be performed on the data obtained. <h3>Results:</h3> Seventeen patients have been prescribed either ravulizumab or efgartigimod. Eleven patients are waiting for approval or infusion scheduling, five have received their first infusion and are scheduled for follow-up in clinic. Two patients had completed their first infusions of ravulizumab and had follow-up data. The study is ongoing with hopes to have data from 25–50 patients in the coming months. <h3>Conclusions:</h3> The study is presently ongoing. <b>Disclosure:</b> Dr. Anderson has nothing to disclose. Dr. Jawdat has nothing to disclose. Dr. Jabari has nothing to disclose. Dr. Chandrashekhar has nothing to disclose. Dr. Farmakidis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Momenta. Dr. Farmakidis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EcoR1 Capital, LLC. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cello Health BioConsulting, previously Defined Health. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CSL Behring. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Octapharma. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ArgenX. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for RAF-5. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Houston NeuroCare. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Shire. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Catalyst. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kezar. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for RaPharma/UCB. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ArgenX. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. An immediate family member of Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kezar. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Catalyst. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SCHOLAR Rock. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jenssen. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amazentis. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roivant. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SANEM. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medlink. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CSL Behring. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Third Rock. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orphazyme . Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kanssen. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roivant . Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Covance / Labcorp. The institution of Dr. Dimachkie has received research support from CSL Behring. The institution of Dr. Dimachkie has received research support from Orphazyme. The institution of Dr. Dimachkie has received research support from FDA-OOPD. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received publishing royalties from a publication relating to health care. Dr. Pasnoor has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx BVBA. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for catalyst. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda Pharmaceuticals. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Pharmaceutical. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for catalyst pharmaceuticals. Dr. Pasnoor has received research support from NIH." @default.
• W4367302912 created "2023-04-29" @default.
• W4367302912 creator A5009597156 @default.
• W4367302912 creator A5037992179 @default.
• W4367302912 creator A5051045476 @default.
• W4367302912 creator A5055953731 @default.
• W4367302912 creator A5057325944 @default.
• W4367302912 creator A5065154579 @default.
• W4367302912 creator A5066596486 @default.
• W4367302912 date "2023-04-25" @default.
• W4367302912 modified "2023-10-05" @default.
• W4367302912 title "Real World Experience of New MG Therapies: Single Center Cohort Study (P7-8.012)" @default.
• W4367302912 doi "https://doi.org/10.1212/wnl.0000000000204073" @default.
• W4367302912 hasPublicationYear "2023" @default.
• W4367302912 type Work @default.
• W4367302912 citedByCount "0" @default.
• W4367302912 crossrefType "proceedings-article" @default.
• W4367302912 hasAuthorship W4367302912A5009597156 @default.
• W4367302912 hasAuthorship W4367302912A5037992179 @default.
• W4367302912 hasAuthorship W4367302912A5051045476 @default.
• W4367302912 hasAuthorship W4367302912A5055953731 @default.
• W4367302912 hasAuthorship W4367302912A5057325944 @default.
• W4367302912 hasAuthorship W4367302912A5065154579 @default.
• W4367302912 hasAuthorship W4367302912A5066596486 @default.
• W4367302912 hasConcept C126322002 @default.
• W4367302912 hasConcept C185592680 @default.
• W4367302912 hasConcept C2522767166 @default.
• W4367302912 hasConcept C2779463800 @default.
• W4367302912 hasConcept C2780073493 @default.
• W4367302912 hasConcept C3018095205 @default.
• W4367302912 hasConcept C3020493868 @default.
• W4367302912 hasConcept C41008148 @default.
• W4367302912 hasConcept C71924100 @default.
• W4367302912 hasConcept C72563966 @default.
• W4367302912 hasConcept C8010536 @default.
• W4367302912 hasConceptScore W4367302912C126322002 @default.
• W4367302912 hasConceptScore W4367302912C185592680 @default.
• W4367302912 hasConceptScore W4367302912C2522767166 @default.
• W4367302912 hasConceptScore W4367302912C2779463800 @default.
• W4367302912 hasConceptScore W4367302912C2780073493 @default.
• W4367302912 hasConceptScore W4367302912C3018095205 @default.
• W4367302912 hasConceptScore W4367302912C3020493868 @default.
• W4367302912 hasConceptScore W4367302912C41008148 @default.
• W4367302912 hasConceptScore W4367302912C71924100 @default.
• W4367302912 hasConceptScore W4367302912C72563966 @default.
• W4367302912 hasConceptScore W4367302912C8010536 @default.
• W4367302912 hasLocation W43673029121 @default.
• W4367302912 hasOpenAccess W4367302912 @default.
• W4367302912 hasPrimaryLocation W43673029121 @default.
• W4367302912 hasRelatedWork W2407672554 @default.
• W4367302912 hasRelatedWork W2603773853 @default.
• W4367302912 hasRelatedWork W2748952813 @default.
• W4367302912 hasRelatedWork W2765712373 @default.
• W4367302912 hasRelatedWork W2899084033 @default.
• W4367302912 hasRelatedWork W2999710862 @default.
• W4367302912 hasRelatedWork W3090707124 @default.
• W4367302912 hasRelatedWork W4200143921 @default.
• W4367302912 hasRelatedWork W4206623210 @default.
• W4367302912 hasRelatedWork W4246780179 @default.
• W4367302912 isParatext "false" @default.
• W4367302912 isRetracted "false" @default.
• W4367302912 workType "article" @default.